Cereplast Reports Financial Results for the First Nine Months of 2013

Cereplast, Inc. Logo

SEYMOUR, Ind., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Cereplast, Inc. (OTCQB:CERP) (the "Company"), a leading manufacturer of proprietary biobased, compostable and sustainable bioplastics, today announced $2.1 million in revenue during the first nine months of 2013 compared to $786,000 for the same period the prior year and a total of $911,000 for the 2012 full year.

Cereplast Chairman and Chief Executive Officer Mr. Frederic Scheer stated, "We are pleased with the year-over-year growth we have experienced for the first nine months of 2013 and we expect to continue this trend as the global market opportunity continues to increase. The most immediate growth driver is the ongoing legislation in Italy for the sanctions of traditional plastic bags. We continue to work closely with customers who are capable of placing orders much larger than they are today in the anticipation of the ruling."

Mr. Scheer continued, "Italy and subsequent European countries have created an immense opportunity for us but we are not putting all of our eggs in one basket. We foresee India and the United States as significant markets for us as well. Both markets are already enforcing sanctions in select areas. We have feet on the ground in each market and are beginning to secure contracts by first educating the marketplace about the benefits of our technology. In India we recently received a $1.4 million order and in the U.S. we are actively pursuing 30 projects with a potential value of over $10 million per year. We anticipate continued traction in both markets."

2013 Industry, Financial and Operational Highlights to Date:

  • Revenue for the first nine months of 2013 totaled $2.1 million.
  • In a recent document, the European Union Environmental Commission stated that they are in support of an amendment to this legislation, which is scheduled to go into effect in November and member states will have two years to comply.
  • Cereplast has estimated annual revenue potential from Italy alone to exceed $50 million.
  • For the past 18 months, the Company has worked closely with over 70 companies in Italy that have completed multiple successful tests with various grades of their blown film resins.
  • In India, Cereplast recently received a $1.4 million purchase order, which will ship over the next 10 months.
  • Additionally, Cereplast received five purchase orders in India totaling $450,000 for blown film resins which will be delivered throughout the remainder of 2013.
  • In the United States, regional and federal laws are supporting growth of the bioplastics industry as seen by movements in San Francisco, Portland and New York City.
  • Cereplast has valued the bioplastic industry in the United States today to be $180 million and expects to begin generating meaningful revenue in 2014.
  • Cereplast is actively pursuing 30 projects in North America with potential value of $10 million per year.
  • Cereplast recently launched reVive™ bioplastic resins, the first bioplastics to combine recycled polymers with biobased resins for improved sustainability, reducing the carbon footprint of this type of bioplastic by adding the environmental benefits of recycled plastic.

2013 First Nine Months Financial Results:

Net sales for the nine months ended September 30, 2013 were approximately $2.1 million, compared to $0.8 million in the same period in 2012. Sales increased from the prior year due to growing demand in European markets primarily due to anticipated legislation in Italy banning traditional plastic bags.

Cost of sales is comprised of variable costs associated with product revenues. Cost of sales for the nine months ended September 30, 2013 was approximately $1.9 million, compared to $0.9 million for the same period in 2012. The increase in cost of sales is due to an increase in sales.

Gross profit (loss) for the nine months ended September 30, 2013 was approximately $0.3 million, compared to ($0.1) million for the same period in 2012. The increase in gross profit was attributable to an increase in sales, as stated above.

Research and development expenses for the nine months ended September 30, 2013 were $0.3 million, compared to approximately $0.4 million for the same period in 2012. Research and development expenses have slightly decreased due to a cost containment effort to preserve working capital.

Selling, general and administrative expenses for the nine months ended September 30, 2013 were $3.8 million, compared to $10.5 million for the same period in 2012. The decrease in sales, general and administrative expenses was primarily due to bad debt expense of $5.1 million recorded in the third quarter of 2013. In addition, the sales, general and administrative expenses decreased due to reduced headcount and a reduction in fixed production overhead costs classified as selling, general and administrative expense due to an extended period of abnormally low production volume.

Other income and expense, net for the nine months ended September 30, 2013 was a net expense of $29.6 million, as compared to a net expense of $5.3 million in the same period in 2012. The increase in expense was primarily a result of the change in our derivative liability related to our warrants, short-term convertible debt and preferred stock agreements. In addition, we recorded $2.8 million in debt extinguishment costs related to the exchange of certain of our term loan and convertible notes.

Net loss for the nine months ended September 30, 2013 was $34 million, as compared to $16.3 million in the same period in 2012. The increase in net loss was primarily driven by an increase in Other Expense related to financing transactions. As discussed above, Other Income and Expense, net was unfavorably impacted by losses on derivative liabilities totaling $21.6 million. The increase in net loss was partially offset by a decrease in bad debt expense recorded in the first nine months of 2013 compared to the first nine months of 2012.

Conference Call Details:
Date: Thursday, November 14th
Time: 4:30 p.m. Eastern
Participant Dial-In: (480) 629-9761
Live Webcast: http://www.cereplast.com/investors/events-presentations/

It is recommended that participants dial in approximately 10 minutes prior to the start of the 4:30 p.m. Eastern call. There will also be a simultaneous live webcast of the conference call which can be accessed through the following audio feed link and archived recording of the conference call available under the Investor Relations section of the company website at http://www.cereplast.com/investors/events-presentations/.

About Cereplast, Inc.

Cereplast, Inc. (OTCQB:CERP) designs and manufactures proprietary biobased, sustainable bioplastics which are used as substitutes for traditional plastics in all major converting processes - such as injection molding, thermoforming, blow molding and extrusions - at a pricing structure that is competitive with traditional plastics. On the cutting-edge of biobased plastic material development, Cereplast now offers resins to meet a variety of customer demands. Cereplast Compostables® resins are ideally suited for single-use applications where high biobased content and compostability are advantageous, especially in the food service industry. Cereplast Sustainables® resins combine high biobased content with the durability and endurance of traditional plastic, making them ideal for applications in industries such as automotive, consumer electronics and packaging. Learn more at www.cereplast.com. You may also visit the Cereplast social networking pages at Facebook.com/Cereplast, Twitter.com/Cereplast and Youtube.com/Cereplastinc.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

(in thousands, except shares data)
September 30, 2013 December 31, 2012
Current Assets
Cash $ 233 $ 183
Accounts Receivable, Net 1,021 149
Inventory, Net 5,722 6,941
Prepaid Expenses and Other Current Assets 199 227
Total Current Assets 7,175 7,500
Property and Equipment
Property and Equipment 11,152 11,601
Accumulated Depreciation and Amortization (4,660) (4,004)
Property and Equipment, Net 6,492 7,597
Other Assets
Restricted Cash -- 43
Deferred Loan Costs 350 750
Intangible Assets, Net 239 245
Deposits 48 47
Total Other Assets 637 1,085
Total Assets $ 14,304 $ 16,182
Current Liabilities
Accounts Payable $ 920 $ 803
Accrued Expenses 3,386 3,663
Capital Leases, Current Portion 97 85
Loan Payable, Current Portion 6,224 5,978
Convertible Subordinated Notes, Current Portion 1,122 891
Derivative Liability 15,142 3,189
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; 490 and 92 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively 2,213 500
Total Current Liabilities 29,104 15,109
Long-Term Liabilities
Loan Payable -- 923
Convertible Subordinated Notes 7,500 10,000
Capital Leases, Long-Term 120 173
Total Long-Term Liabilities 7,620 11,096
Total Liabilities 36,724 26,205
Shareholders' Deficit
Common Stock, $0.001 par value; 2,000,000,000 shares authorized; 810,757,671 and 63,463,659 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively 811 63
Common Stock Subscribed, not issued 1,358 --
Additional Paid in Capital 96,416 76,919
Accumulated Deficit (121,136) (87,097)
Accumulated Other Comprehensive Income 127 88
(22,424) (10,027)
Noncontrolling Interests 4 4
Total Shareholders' Deficit (22,420) (10,023)
Total Liabilities and Shareholders' Deficit $ 14,304 $ 16,182
(unaudited, in thousands, except per share data)
Three Months Ended Nine Months Ended
September 30, 2013 September 30, 2012 September 30, 2013 September 30, 2012
Gross Product Sales $ 438 $ 481 $ 2,135 $ 786
Sales Discounts, Returns and Allowances (2) (4) (3) (16)
Net Sales 436 477 2,132 770
Cost of Goods Sold 382 473 1,880 861
Gross Profit (Loss) 54 4 252 (91)
Operating Expenses:
Research and Development 75 115 295 370
Selling, General and Administrative 1,134 6,847 3,796 10,519
Impairment of Long-Lived Assets 547 -- 547 --
Total Operating Expenses 1,756 6,962 4,638 10,889
Operating Loss (1,702) (6,958) (4,386) (10,980)
Debt Extinguishment Costs (1,065) -- (2,821) (427)
Change in Derivative Liabilities (2,392) 47 (21,629) (52)
Interest and Other Income -- -- -- 18
Interest Expense (2,112) (3,057) (5,203) (4,834)
Loss Before Provision for Income Taxes (7,271) (9,968) (34,039) (16,275)
Provision for Income Taxes -- -- -- --
Net Loss $ (7,271) $ (9,968) $ (34,039) $ (16,275)
Net Loss Per Share - Basic and Diluted $ (0.01) $ (0.40) $ (0.07) $ (0.77)
Weighted Average Common Shares Outstanding - Basic and Diluted 731,817,081 24,739,449 482,042,209 21,242,115
(unaudited, in thousands, except shares data)
Nine Months Ended
September 30, 2013 September 30, 2012
Net Loss $ (34,039) $ (16,275)
Adjustment to Reconcile Net Loss to Net Cash Used in Operating Activities
Depreciation and Amortization 665 536
Allowance for Doubtful Accounts 3 5,082
Common Stock Issued for Services, Salaries and Wages 171 160
Amortization of Loan Discount 4,230 3,223
Extinguishment of Convertible Debt 2,821 368
Loss on Derivative Liabilities 21,629 52
Impairment of Long-Lived Assets 547 --
Changes in Operating Assets and Liabilities
Accounts Receivable (875) 537
Deferred Loan Costs 400 458
Inventory 1,219 814
Prepaid Expenses 28 (171)
Restricted Cash 43 --
Accounts Payable 116 659
Accrued Expenses 749 288
Purchase of Property and Equipment, and Intangibles (3) (180)
Proceeds from Sale of Equipment -- 15
Payments on Capital Leases (41) (50)
Payments made on Notes Payable (63) (603)
Proceeds from Convertible Notes, Net of Issuance Costs 63 600
Proceeds from Issuance of Preferred Stock 2,750 400
Proceeds from Issuance of Common Stock and Subscriptions, Net of Issuance Costs (23) 400

CONTACT: Cereplast, Inc. Public Relations Nicole Robertson 812.220.5400 X1013 nrobertson@cereplast.com Investor Relations: Alliance Advisors, LLC Valter Pinto 914-669-0222 x201 valter@allianceadvisors.net www.AllianceAdvisors.net

Source:Cereplast, Inc.